CARVEDILOL SOLUBILITY ENHANCEMENT BY INCLUSION COMPLEXATION AND SOLID DISPERSION: REVIEW by Zoghbi, Abdelmoumin & Wang, Bo
Zoghbi et al                   Journal of Drug Delivery & Therapeutics. 2015; 5(2):1-8 1 
© 2011-14, JDDT. All Rights Reserved                     ISSN: 2250-1177                    CODEN (USA): JDDTAO 
Available online on 15.03.2015 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open access to Pharmaceutical and Medical research 
© 2015, publisher and license JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the original work 
is properly cited 
 
REVIEW ARTICLE 
CARVEDILOL SOLUBILITY ENHANCEMENT BY INCLUSION COMPLEXATION AND 
SOLID DISPERSION: REVIEW 
Abdelmoumin Zoghbi, Bo Wang* 
Department of Pharmaceutics, China Pharmaceutical University, #639 Longmian Avenue, Jiangning District, Nanjing, 
P.R. China, 211198 
*Corresponding Author’s E-mail: bwangcpu@hotmail.com  
Received 10 Feb 2015; Review Completed 05 March 2015; Accepted 07 March 2015, Available online 15 march 2015 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
1. INTRODUCTION: 
Carvedilol is an effective nonselective alpha-1 and beta 
blocker discovered by Fritz Wiedemann
[1]
. It is an 
antihypertensive drug indicated for the treatment of mild 
to severe congestive heart failure (CHF), angina pectoris, 
cardiac arrhythmias and myocardial infarction 
[2]
. Water 
solubility of Carvedilol is a fundamental property that 
affects the drug absorption after oral administration. 
Moreover, its dissolution and gastrointestinal 
permeability are the parameters that control its 
bioavailability 
[3]
. The most frequent causes of low oral 
bioavailability is attributed to poor solubility and low 
permeability 
[4]
. Carvedilol is categorized as class II drug 
with low solubility and reasonable membrane 
permeability.  
Cyclodextrins are cyclic (α-1,4)-linked oligosaccharides 
of α-D-glucopyranose, containing a relatively 
hydrophobic central cavity and hydrophilic outer surface 
[5]
. Drug solubility enhancement using Cyclodextrin and 
ABSTRACT: 
Carvedilol is an antihypertensive drug characterized by its low aqueous solubility, a major obstacle in drug formulation 
development to improve its bioavailability. To overcome problem of poor aqueous solubility of Carvedilol, various approaches 
have been investigated including physical and chemical modifications of the drug. Most of these investigations focused on 
modifying the drug structure from crystalline insoluble form to amorphous soluble form, reducing drug particle size to provide 
high surface area subjected to solvent, enhancing porosity degree, and improving wettability. A wide variety of polymers was 
used in order to achieve these goals. Carvedilol inclusion complex with Cyclodextrin (CD) and derivatives, solid dispersion with 
water-soluble carriers such as Polyvinylpyrrolidone K-30 (PVP K-30), Gelucire 50/13, porous silica (Sylysia 350), and 
Soluprus® (polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer) were previously investigated using 
different preparation methods such as Solvent evaporation method, fusion method, kneading method, and spray drying method. 
Analytical tests were conducted to characterize these preparations. FTIR, SEM, DSC, XRD are among the most commonly used. 
The present paper summarizes different drug-carrier combinations used for solubility, dissolution rate and/or bioavailability 
enhancement of Carvedilol, with emphases on the preparation methods of Carvedilol inclusion complex and solid dispersions, 
and different tests used for their characterization. 
Keywords: Carvedilol, solubility enhancement, inclusion complex, solid dispersion, bioavailability. 
Zoghbi et al                   Journal of Drug Delivery & Therapeutics. 2015; 5(2):1-8 2 
© 2011-14, JDDT. All Rights Reserved                     ISSN: 2250-1177                    CODEN (USA): JDDTAO 
derivatives is generally proceed through formation of 
inclusion complexes. Cyclodextrins serve as host and 
form compound with different drug molecules 
[6, 7]
 
(Fig.1).Each drug molecule is enclosed by a Cyclodextrin 
molecule. Cyclodextrins have been widely used to 
enhance the aqueous solubility and dissolution rate of 
poorly water-soluble drugs 
[8, 9]. β-Cyclodextrin and its 
derivatives ( 2-hydroxypropyl-β-cyclodextrin HP-β-CD, 
sulfobutyl ether-β-cyclodextrin SB-β-CD) are the most 
commonly used in the inclusion complex 
[10-13]
. 
Solid dispersion is another approach for drug solubility 
and dissolution enhancement. The concept of solid 
dispersion was proposed by Sekiguchi and Obi
[14]
. Solid 
dispersion, also called solid solution 
[15]
, is widely and 
successfully applied for the solubility, dissolution rate, 
and by consequence bioavailability enhancement of 
poorly water-soluble drugs 
[16]
. It consists of a 
hydrophobic drug dissolved in a hydrophilic matrix, 
which can be amorphous (clusters) or crystalline particles 
[17, 18]
. Solid Dispersions have the advantage of uniformity 
distribution of the drug into carrier. It results in particles 
with amorphous structure 
[19-21]
, reduced particle size, 
higher porosity degree, and improved wettability 
[15, 22, 23]
. 
The dispersion of drug into the carrier is rate limiting. 
Therefore, the formation of solid solution is restricted to 
relatively low concentration of the drug 
[24, 25]
. 
In order to improve the dissolution characteristics of 
carvedilol and enhance its aqueous solubility, several 
investigations have been established such as 
complexation with β-Cyclodextrin[26-28] and solid 
dispersion with different water-soluble carriers.
  
2. SATURATION SOLUBILITY: 
The solubility of a drug is the maximum quantity of drug 
that can dissolve in certain volume of a specific solvent at 
chosen conditions of temperature and pH. It might be 
stated in units of concentration, molarity, mole fraction, 
mole ratio, and other units 
[29]
. In general, solubility is 
defined as an equilibrium thermodynamic parameter, at 
which the chemical potential of the solute in the solid 
phase is the same as that in the liquid (solution) phase 
[30]
. 
Saturation solubility of a drug is used to determine the 
maximum amount of the drug dissolved in a specific 
solvent. It is a preliminary step in any solubility 
enhancement research particularly for poorly 
water-soluble drugs. It can strongly depend on the 
presence of other species in the solvent.  
In general, Solubility measurement is performed 
according to method reported by Higuchi and Connors 
[31]
 
where an excess amount of the drug is dissolved in a 
specific volume of the dissolution medium of a chosen pH. 
The dissolution medium can be pure water or a solution of 
different concentrations of the water-soluble carriers. 
This study is carried out for 24 – 72 hours using 
temperature controller orbital shaker. 
Saturation solubility of Carvedilol is pH-dependent 
because of the ionization and the basic nature of 
Carvedilol
[32]
. Carvedilol remains in a unionized form 
within solutions of high pH. However, it has an 
appreciable solubility in acidic pH 
[33]
. Some surfactants 
might affect Carvedilol solubility. Chakraborty et al.
[33]
 
investigated the effect of different classes of surfactants 
(anionic-sodium dodecyl sulfate SDS and sodium 
taurocholate STC, cationic-cetyltrimethylammonium 
bromide CTAB and non-ionic-Tween 80) on the solubility 
of Carvedilol in different pH. Each of the surfactants 
showed a remarkable enhancement in the solubility of 
 
 
Fig.1: Schematic representation of Drug-Cyclodextrin interaction in molecular ratio 1:1. 
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Carvedilol in both acidic and basic pH 
[33]
. 
Solutions containing water-soluble polymers used in the 
solubility study also have a great effect in the solubility, 
and the enhancement is polymer concentration-dependent. 
The presence of β-Cyclodextrin (βCD) or derivate 
(hydroxypropyl-beta-Cyclodextrin HP-βCD) showed an 
improvement in the solubility of Carvedilol
[32, 34, 35]
(fig.2). 
Cyclodextrins profile exhibits AN-type isotherm 
[36]
. 
Therefore, the solubility of the drug molecule increases 
linearly with Cyclodextrin concentration up to certain 
extent and further its deviates negatively 
[32]
. 
 
 
 
 
 
 
 
 
 
 
Other investigations used different polymers (PVP 
K-30
[32, 37]
, Poloxamer 407 
[32]
, HPMC 
[38]
, Gelucire
[39]
, 
some Eudragits
[38]
, PEG 4000, porous silica 
[40]
, 
Soluplus
®[41]
) alone or in combination also showed a 
solubility enhancement of the drug. After plotting 
Carvedilol solubility versus carrier concentration, the 
apparent complexation constant (Kc) of the solid 
dispersions can be calculated using the equation: 
𝐾𝑐 =
𝑆𝑙𝑜𝑝𝑒
𝑆0(1 − 𝑆𝑙𝑜𝑝𝑒)
 
Where S0 is the intrinsic solubility of the drug in absence 
of Carrier. 
 
3. CARVEDILOL SOLUBILITY 
ENHANCEMENT TECHNIQUES: 
3.1. Carvedilol-Cyclodextrin inclusion complexation: 
Several recent investigations showed that the inclusion 
complex is effective in the solubility and dissolution rate 
enhancement of Carvedilol. β-Cycldodextrin can reduce 
the interfacial tension between the solid particles of pure 
drug 
[42]
 because of its surfactant-like property. This 
improvement is guest/host ratio-dependent. The molar 
ratio of 1:3 (Carvedilol: β Cyclodextrin) showed a high 
and rapid dissolution rate in acidic media pH 1.2 
[43]
. 
Preparation method of the inclusion complex as well can 
affect the dissolution rate. A variety of methods used to 
prepare Carvedilol-Cyclodextrin inclusion complexes: 
3.1.1. Solvent evaporation method: 
Solvent evaporation method is the most commonly used 
method when the experiment concerns complexation of 
two compounds. The method was evaluated by Tachibana 
and Nakamura 
[44]
 when they dissolved both drug and 
carrier in a common solvent to have a clear solution, then 
the solvent was evaporated under vacuum to have the 
complex in solid form. In the case of Carvedilol-β 
Cyclodextrin inclusion complex, this method is less 
effective comparing to other methods. 
3.1.2. Kneading method: 
Mostly used in industry when a big quantity of the 
complex is needed. An aqueous Cyclodextrin paste is 
prepared, using mortar and pestle in laboratory or 
kneading machine in large scale, by adding a small 
volume of solvent, which can be pure water or mixed with 
methanol. A specific amount of the drug is added to the 
paste while keeping vigorous stirring for 1 – 4 hours. 
Complex formation is indicating by the increasing 
viscosity of the mixture. The paste is then dried under 
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Fig 2: Solubility diagram of carvedilol in presence of β-CD and HP-β-CD 
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vacuum at temperature 40 – 60˚C [42, 43, 45], and ground to 
obtain the complex powder. 
3.1.3. Freeze-drying method: 
This method is an alternative to solvent evaporation 
method. The drug and carrier molecules are mixed in a 
common solvent 
[46]
. It involves an amorphous form of the 
complex with high interaction between Carvedilol and 
Cyclodextrin. It consists of freezing the solution 
containing the complex then allows the frozen solvent to 
sublimate by reducing the surrounding pressure. The 
freeze speed has an effect on the product form. It was 
found that slow freezing provided crystalline products, 
while rapid freezing provided amorphous inclusion 
complexes 
[47]
. 
3.1.4. Coprecipitation method: 
Coprecipitation is a phenomenon where a solute that 
would normally remain dissolved in a solution 
precipitates out on a carrier that forces it to bind together, 
rather than remaining dispersed 
[48]
. Carvedilol was 
dissolved in methanol, the solution was then added 
dropwise into Cyclodextrin solution with continuous 
vigorous stirring. Crystals of a Cyclodextrin are formed 
and Carvedilol finds holes in the crystal matrix to occupy. 
The precipitate explains the inclusion complex formation. 
The remaining solvent were removed by desiccation 
under vacuum 
[42]
 or rotary evaporator 
[49]
.  
3.2. Carvedilol solid dispersion: 
Solid dispersion is one of several methods to increase 
solubility and dissolution rate of Carvedilol. For this 
purpose, different methods and carriers are utilized: 
3.2.1. Solvent evaporation method: 
Organic solvents are used to dissolve both the carrier and 
the drug. There is no thermal destruction of the drug 
because low temperature is required to evaporate organic 
solvent under vacuum 
[50]
. Carvedilol solid dispersion 
using solvent evaporation method is recommended with 
wide variety of carriers such as: PVP K-30 
[37, 51]
, Tartaric 
Acid and Poloxamer 407 
[32]
, Gelucire 50/13
[39]
, porous 
silica 
[52]
, and Soluprus
®[53]
. 
3.2.1.1. Carvedilol-PVP solid dispersion: 
Carvedilol and PVP were taken in the weight ratio 1:1, 1:3 
and 1:5. Generally, the solvent used is methanol. When a 
clear solution was formed, the solvent evaporated under 
vacuum at temperature about 50˚C. The resultant solid 
mass was crashed, desiccated and finally evaluated using 
in-vitro dissolution tester. Different dissolution media can 
be used (acidic pH 1.2, PBS of different pH and pure 
water). Dissolution rates of Carvedilol-PVP solid 
dispersion at different ratios in simulated gastric fluid are 
summarized in (table 1)
[37]
. PVP improves Carvedilol 
wettability and, because of its high glass transition 
temperature (Tg), prevents Carvedilol recrystallization 
through nucleation 
[54]
. 
3.2.1.2. Carvedilol-Gelucire 50/13 solid dispersion: 
An appropriate amount of Gelucire was added to 
Carvedilol solution in a mixture of acetone and 
dichloromethane taken in 1:1 ratio 
[39]
. The solvent was 
then evaporated under vacuum using rotary evaporator at 
40˚C. In-vitro dissolution test results of the obtained solid 
dispersion in pure distilled water are showed in (table 
1)
[39]
. The results showed a significantly higher 
dissolution profiles comparing to the pure drug due to the 
amorphous structure and improved wettability of 
Carvedilol in solid dispersion.  
3.2.1.3. Carvedilol-porous silica solid dispersion: 
Solid dispersion consists of Carvedilol loading into the 
porous silica. Solvent evaporation under vacuum and 
adsorption from acetone solution were the methods used 
[40]
. Porous Silica was suspended in a specific amount of 
carvedilol solutions in acetone (1%, 2%, and 4%, w/v). 
The solvent was evaporated in a vacuum evaporator at 
50˚C to ensure an effective pore-filling procedure [52]. 
Dissolution experiments was conducted in phosphate 
buffer (pH 6.8) and the results are shown in (table 1)
[40]
. 
As hypothesized by Monkhouse and Lach
[55]
, the rapid 
drug release in phosphate buffer can be explained by the 
rapid desorption of Carvedilol from silica in presence of 
water. 
3.2.1.4. Carvedilol-Soluprus solid dispersion : 
Polyvinyl caprolactam–polyvinyl acetate–polyethylene 
glycol graft copolymer (Soluplus®) is designed for solid 
solutions because of its amphiphlic properties. It can be 
classified in the fourth generation of solid dispersion 
members because it serves as a matrix polymer for solid 
solutions and an active solubilizer through micelle 
formation in water 
[56]
. Solid dispersion was prepared by 
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adding a solution of Carvedilol in methanol onto the 
copolymer, triturated with a pestle, and then kept to dry in 
desiccators over anhydrous calcium chloride 
[57]
. In-vitro 
dissolution test was carried out using distilled water. The 
rapid dissolution of Carvedilol from the solid dispersion 
may be attributed to its molecular and colloidal dispersion 
in the hydrophilic carrier matrix. As the soluble carrier 
dissolves, Carvedilol, in the form of very fine particles, is 
exposed to dissolution medium and the consequent 
increase in the surface area results in the improved 
dissolution 
[58]
. 
3.2.2. Fusion method: 
This method cannot be processed in the case of 
thermolabile drugs. The carrier is heated at temperature 
just above its melting point, and then the drug is dissolved 
in the melted matrix with constant stirring for a specific 
time to homogenously disperse the drug into the matrix 
[59]
. The mixture is cooled at room temperature or using 
ice-bath. Carvedilol solid dispersion with Poloxamer 188 
(PLX188) were conducted using fusion method 
[60]
. 
Dissolution test were performed using distilled water as 
medium and the results are shown in (table 1)
[60]
. The 
increased dissolution rate of Carvedilol in solid 
dispersion can be explained by the amorphous state of the 
drug. The polymer might acts by tension lowering effect 
of polymer to the medium and, by consequence, improved 
wettability of Carvedilol. 
3.2.3. Spray drying method: 
Solid dispersion by spray drying method improves the 
dissolution property of a drug by combining a poorly 
soluble drug and a hydrophilic carrier 
[35]
. This method 
was found to be effective in the preparation of 
Carvedilol-HPMC solid dispersion
[61]
. Carvedilol and 
HPMC, at different ratios were dissolved in a co-solvent 
of methylene chloride and methanol with the volume ratio 
1:1. The suspension was prepared as solid dispersion 
using spray dryer under the condition showed in (table 
2)
[61]
. In-vitro dissolution test showed a sustained release 
of Carvedilol during 120mn of dissolution period. These 
results might be explained by the fact that HPMC was 
swelled by water and slowly released Carvedilol
[62]
.
 
Table 1: Dissolution study of different Carvedilol solid dispersions in different mediums 
Medium Carrier Drug:carrier 
ratio (w:w) 
Preparation 
method 
Dissolution 
rate at 10mn 
Dissolution rate 
at 120mn 
t50% (mn) 
Pure 
water 
PLX188 
[60]
 1:0 Fusion 
method 
1.93% 17% >120 
1:1 46.25% 76.60% <20 
1:3 54.5% 86.186% <10 
1:5 59.75% 93.214% <10 
Gelucire 
[39]
 1:0 Solvent 
evaporation 
method 
1.93% 17% >120 
1:1 26.58±0.27% 61% 51.8±1.03 
1:3 37.66±1.10% 72% 41.33±0.57 
1:5 49.015±0.27% 88% 15.76±0.25 
1:7 57.78±0.57% 99% 12.13±0.11 
1:9 67.56±0.73% 100% 10.06±0.11 
PBS pH 
6.8 
Porous 
silica 
[40]
 
1:0 Solvent 
evaporation 
method 
5.33±0.33% 23% >120 
1:1 59.30±2.00% 90.6% <20 
1:3 64.00±0.27% 100% <10 
1:5 78.01±1.33% 100% <10 
Simulated 
gastric 
fluid pH 
1.2 
PVP K-30 
[37]
 
1:0 Solvent 
evaporation 
method 
2.6% 6.5% >120 
1:1 45% 75% <120 
1:3 50% 82% <100 
1:5 60% 90% <10 
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Table 2: 
[61]
.Parameters of spray drying. 
Parameter Setting 
Inlet temperature 
Outlet temperature 
Atomizing 
Row rate 
Pump speed 
130˚C 
75±5˚C 
10 10 kPa 
0.45 m
3
/mn 
3.0 mL/mn 
 
4. COMPLEX AND SOLID DISPERSIONS 
CHARACTERIZATION 
The pure drug, inclusion Complexes and solid dispersions 
can be characterized by several analytic methods:  
 Fourier Transform InfraRed spectroscopy (FTIR)[63] 
identifies chemical bonds in a molecule by producing 
an infrared absorption spectrum. Thus, it is effective 
for detecting functional groups in a compound by their 
different vibrational modes.  
 Scanning Electron Microscopy (SEM) provides 
information about the sample's surface topography 
and identifies the morphology of the particles.  
 Powder X-ray Diffractometry (XRD) is used for the 
structural characterization of materials 
[64]
 and 
determines the crystal structure of powders. 
 Thermal analysis: Differential Thermal Analysis (DTA) 
and Differential Scanning Colorimetry (DSC) are 
alternative techniques used to measure the crystalline 
phase transition temperature and energy. 
5. CONCLUSION 
Carvedilol aqueous solubility has been successfully 
improved by different combination methods. Both 
inclusion complex and solid dispersion can form stable 
complexes between Carvedilol and carriers. The 
interaction between them might be slightly influenced by 
preparation method. However, increasing carrier content 
in the complex can rise the drug solubility. The crystalline 
form of the drug is converted to amorphous metastable 
state. The new morphological form of Carvedilol is 
confirmed by different characterization tests.
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